JAK1 and sarcoidosis: We and others have recently described effective treatment of individual patients with sarcoidosis using tofacitinib (JAK1/3 > 2 inhibitor) or ruxolitinib (JAK1/2 inhibitor); however, this approach has not yet been evaluated in a prospective fashion and the key cytokines targeted remain to be fully elucidated19–25.